|
Priorities for 2021
|
Key achievements to date
|
Drive the development & availability of affordable, transformative, digitally-integrated tests
|
- Develop low-cost, well-performing antigen rapid tests (Ag RDTs), with regionalized manufacturing capacity
- Develop affordable, well-performing multi-pathogen testing platforms
- Design market interventions to make well-performing diagnostic tools available & affordable (including self-tests)
- Develop non-proprietary test result reader app and interoperability solution to integrate with diagnostic tests
- Continue to update open access resources (including landscaping, biobanking, performance benchmarking panels)
- Create mechanism to aggregate country demand
|
|
Secure equitable access to tests
|
- Procure 85 million tests to cover immediate LMICs need; 500 million tests needed by the end of 2021
|
- Procured over 27 million molecular tests and 12 million rapid antigen tests for LMICs; more information on procurement available from the Global Fund
|
Stimulate rapid & effective country uptake
|
- Strengthen testing infrastructure & capacity in low-income countries
- Generate evidence for policymakers & implementers through operational research, deploy catalytic funding in countries to optimally implement tests (including innovative delivery models)
- Build capabilities and provide support to healthcare workers & laboratorians through training & technical assistance for countries
|
|
